Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson's Disease.

IF 2.2 4区 医学 Q3 CLINICAL NEUROLOGY
Parkinson's Disease Pub Date : 2026-07-31 eCollection Date: 2026-01-01 DOI:10.1155/padi/8827381
Yasushi Osaki, Yukari Morita, Sho Ohtsuru, Tomohiro Shogase, Daiji Yoshimoto, Tatsuya Ikeda, Sayomi Kabeya, Yu Hashimoto, Takuya Matsushita
{"title":"Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson's Disease.","authors":"Yasushi Osaki, Yukari Morita, Sho Ohtsuru, Tomohiro Shogase, Daiji Yoshimoto, Tatsuya Ikeda, Sayomi Kabeya, Yu Hashimoto, Takuya Matsushita","doi":"10.1155/padi/8827381","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) patients under medical treatment experience motor complications (MCs), namely, ON/OFF fluctuations (ON/OFF) and dyskinesias.</p><p><strong>Methods: </strong>We assessed 120 newly diagnosed PD patients after the initiation of medical treatment who were followed up for at least 24 months. We reviewed the latency of ON/OFF or dyskinesias by months and calculated the levodopa dose (LD), levodopa dose divided by daily intake (LDdiv), and levodopa equivalent dose (LED). We estimated cumulative incidence and median latency by Kaplan-Meier survival analysis. We classified patients with MCs into four groups and patients with ON/OFF or dyskinesias into three groups, according to latency.</p><p><strong>Results: </strong>Seventy-six patients experienced MCs with a median latency of 28 months. Fifty-seven patients experienced ON/OFF and 19 experienced dyskinesias with a median latency of 28 and 50 months, respectively. The medication dose at which each patient experienced ON/OFF or dyskinesias varied widely. The median LD, LDdiv, and LED was 300 (237.5-350), 100 (79-111), and 300 (250-450) mg at the onset of MCs; 300 (200-300), 100 (83-125), and 300 (249-400) mg at the onset of ON/OFF; and 400 (375-500), 125 (105-133), and 600 (466-722.75) mg at the onset of dyskinesias, respectively. Consistently, the shortest latency group had the lowest medication dose, while the longest latency group had the highest. Five patients experienced dyskinesias before ON/OFF, with similar medication doses at the onset of ON/OFF and dyskinesias. Some patients experienced ON/OFF but have not yet developed dyskinesias under a comparable medication dose as patients who experienced dyskinesias; the latter had a significantly younger age at onset.</p><p><strong>Conclusions: </strong>The pathophysiological backgrounds and changes causing ON/OFF or dyskinesias are not the same for all patients. The presence of ON/OFF and higher medication doses does not always cause dyskinesias. A younger age at onset may be associated with the occurrence of dyskinesias.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2026 ","pages":"8827381"},"PeriodicalIF":2.2000,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424818/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/padi/8827381","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Parkinson's disease (PD) patients under medical treatment experience motor complications (MCs), namely, ON/OFF fluctuations (ON/OFF) and dyskinesias.

Methods: We assessed 120 newly diagnosed PD patients after the initiation of medical treatment who were followed up for at least 24 months. We reviewed the latency of ON/OFF or dyskinesias by months and calculated the levodopa dose (LD), levodopa dose divided by daily intake (LDdiv), and levodopa equivalent dose (LED). We estimated cumulative incidence and median latency by Kaplan-Meier survival analysis. We classified patients with MCs into four groups and patients with ON/OFF or dyskinesias into three groups, according to latency.

Results: Seventy-six patients experienced MCs with a median latency of 28 months. Fifty-seven patients experienced ON/OFF and 19 experienced dyskinesias with a median latency of 28 and 50 months, respectively. The medication dose at which each patient experienced ON/OFF or dyskinesias varied widely. The median LD, LDdiv, and LED was 300 (237.5-350), 100 (79-111), and 300 (250-450) mg at the onset of MCs; 300 (200-300), 100 (83-125), and 300 (249-400) mg at the onset of ON/OFF; and 400 (375-500), 125 (105-133), and 600 (466-722.75) mg at the onset of dyskinesias, respectively. Consistently, the shortest latency group had the lowest medication dose, while the longest latency group had the highest. Five patients experienced dyskinesias before ON/OFF, with similar medication doses at the onset of ON/OFF and dyskinesias. Some patients experienced ON/OFF but have not yet developed dyskinesias under a comparable medication dose as patients who experienced dyskinesias; the latter had a significantly younger age at onset.

Conclusions: The pathophysiological backgrounds and changes causing ON/OFF or dyskinesias are not the same for all patients. The presence of ON/OFF and higher medication doses does not always cause dyskinesias. A younger age at onset may be associated with the occurrence of dyskinesias.

新诊断和治疗帕金森病患者运动并发症的发生与用药剂量
背景:接受药物治疗的帕金森病患者会出现运动并发症(MCs),即ON/OFF波动(ON/OFF)和运动障碍。方法:我们对120例新诊断的PD患者进行了至少24个月的随访。我们以月为单位回顾了ON/OFF或运动障碍的潜伏期,并计算了左旋多巴剂量(LD)、左旋多巴剂量除以日摄入量(LDdiv)和左旋多巴等效剂量(LED)。我们通过Kaplan-Meier生存分析估计累积发病率和中位潜伏期。根据潜伏期,我们将MCs患者分为四组,将ON/OFF或运动障碍患者分为三组。结果:76例患者出现MCs,中位潜伏期为28个月。57名患者出现ON/OFF, 19名患者出现运动障碍,中位潜伏期分别为28个月和50个月。每个患者经历开/关或运动障碍的药物剂量差异很大。MCs发病时LD、LDdiv和LED的中位数分别为300(237.5-350)、100(79-111)和300 (250-450)mg;300(200-300)、100(83-125)和300 (249-400)mg的开启/关闭;运动障碍发病时分别为400(375-500)、125(105-133)和600 (466-722.75)mg。潜伏期最短组用药剂量最低,而潜伏期最长组用药剂量最高。5例患者在开/关之前出现运动障碍,在开/关和运动障碍开始时的药物剂量相似。一些患者经历了开/关,但在与经历运动障碍的患者相当的药物剂量下尚未发生运动障碍;后者的发病年龄明显较年轻。结论:导致ON/OFF或运动障碍的病理生理背景和变化在所有患者中并不相同。开/关的存在和较高的药物剂量并不总是导致运动障碍。较年轻的发病年龄可能与运动障碍的发生有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Parkinson's Disease
Parkinson's Disease CLINICAL NEUROLOGY-
CiteScore
5.80
自引率
3.10%
发文量
0
审稿时长
18 weeks
期刊介绍: Parkinson’s Disease is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the epidemiology, etiology, pathogenesis, genetics, cellular, molecular and neurophysiology, as well as the diagnosis and treatment of Parkinson’s disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书